



Integrating Herbal Medicine and Artificial Intelligence in Cancer Identification and Treatment: A Review Article

Geeta Chaudhary

Department of Biotechnology, S.S. Jain Subodh P.G. College, Jaipur, Rajasthan, India.

ABSTRACT

Cancer remains one of the most challenging diseases to treat, necessitating novel and integrated approaches for its identification and management. This review explores the potential synergy between herbal medicine and artificial intelligence (AI) in the realm of cancer diagnosis, prognosis, and treatment. Herbal medicine offers a vast repertoire of bioactive compounds with therapeutic potential, while AI algorithms provide sophisticated analytical tools for data processing and pattern recognition. By integrating these two domains, promising avenues for personalized and targeted cancer care emerge. This review critically examines the current landscape, challenges, and future prospects of leveraging herbal medicine and AI in the fight against cancer.

Key Words: AI algorithms, Cancer detection, Herbal Drugs, Cancer treatment, Malignant transformation, Herbal Therapies.

INTRODUCTION

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.¹ Cancer is fundamentally a disease of tissue growth regulation. For a normal cell to transform into a cancer cell, the genes that regulate cell growth and differentiation must be altered.²

The affected genes are divided into two broad categories. Oncogenes are genes that promote cell growth and reproduction. Tumor suppressor genes are genes that inhibit cell division and survival. Malignant transformation can occur through the formation of novel oncogenes, the inappropriate over-expression of normal oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, changes in multiple genes are required to transform a normal cell into a cancer cell (Fig. 1).³

These contrast with benign tumors, which do not spread.⁴ Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements.⁵




Figure 1: Cancer Initiation Stages.

Corresponding Author:

Dr. Geeta Chaudhary, Department of Biotechnology, S.S. Jain Subodh P.G. College, Jaipur, Rajasthan, India.
Phone: 9414371441; Email: gchaudhary25@gmail.com

ISSN: 2231-2196 (Print)

ISSN: 0975-5241 (Online)

Received: 12.02.2025

Revised: 09.03.2025

Accepted: 26.03.2025

Published: 11.04.2025

Cancer continues to pose a significant global health burden, necessitating innovative strategies for its prevention, diagnosis, and treatment. In some Western countries such as the USA and UK, cancer is overtaking cardiovascular disease as the leading cause of death. In the USA and other developed countries, cancer is presently responsible for about 25 per cent of all deaths.⁶

Cancer arises due to uncontrolled cell growth triggered by genetic mutations and environmental factors. The primary causes of different types of cancer vary but commonly include genetic predisposition, lifestyle choices, and environmental exposures. For instance, lung cancer is strongly linked to smoking and air pollution, while skin cancer often results from excessive ultraviolet (UV) radiation from the sun or tanning beds. Breast and ovarian cancers can be influenced by inherited mutations in BRCA1 and BRCA2 genes. Additionally, prolonged exposure to carcinogens like asbestos, alcohol consumption, poor diet, and physical inactivity contribute to various cancer types. Certain infections, such as human papillomavirus (HPV) causing cervical cancer and hepatitis B and C leading to liver cancer, also play significant roles. These factors disrupt normal cell regulation, leading to tumor development and cancer progression.

Traditional approaches to cancer management often include chemotherapy, radiation therapy, and surgery, which may be associated with adverse effects and limited efficacy. In recent years, there has been a growing interest in exploring complementary and alternative therapies, such as herbal medicine, for their potential anticancer properties. At a workshop in Dartmouth in the summer of 1956, coined the term “artificial intelligence (AI)”, also known as “machine intelligence”.⁷ To put it simply, AI is defined as a programmed machine that can learn and recognize patterns and relationships between inputs and outputs and use this knowledge effectively for decision-making on brand-new input data.^{7,8} Concurrently, advances in artificial intelligence (AI) have revolutionized various aspects of healthcare, including cancer detection, risk stratification, and treatment optimization. This review aims to elucidate the synergistic potential of integrating herbal medicine and AI in cancer identification and treatment.

Herbal Medicine in Cancer Therapy

Herbal medicine, derived from plants and natural sources, has been used for centuries in traditional medical systems worldwide. Many herbs contain bioactive compounds with diverse pharmacological effects, including anti-inflammatory, antioxidant, and anticancer properties. Numerous studies have investigated the efficacy of herbal extracts and compounds in inhibiting cancer cell proliferation, inducing apoptosis, and mitigating tumor progression. Interestingly, other studies have shown that long-term uptake of vitamin E may in fact have a negative effect on breast cancer patients.^{9,10}

Currently, their use seems to cause malabsorption or maldigestion in cancer patients suffering from a concomitant illness, moreover, providing patients adopt a balanced and healthy diet.^{11,12} Recent studies based on epidemiological modelling have demonstrated interesting patterns suggesting that herbal treatment may improve prognosis in advanced colon cancer patients when used as an adjuvant.^{13,14} The therapeutic mechanisms of traditional Chinese medicine in metastatic cancer have been discussed in terms of a hypothetical, dualistic antiproliferation and immune-stimulation model of tumor progression and regression.¹⁵

However, despite promising preclinical evidence, rigorous clinical trials are needed to validate the safety and efficacy of herbal medicines in cancer therapy. Curcumin, the active component of turmeric, has exhibited potent antitumor effects in various cancer types, including breast, colorectal, pancreatic, and prostate cancer. Randomized controlled trials (RCTs) (or randomized comparative trials) currently serve as the gold standard for most clinical trials and provide the best evidence of the efficacy of healthcare interventions.¹⁶ Carefully planned and well-executed RCTs often obtain the best estimates of treatment effect and thus help guide clinical decision making; therefore, considerable effort is put into improving the design and reporting of RCTs commented that reporting quality may vary across different types of complementary therapies, with herbal medicine trials being apparently superior to homeopathy and acupuncture trials.^{17,18,19}

Herbal Medicine for Symptom Management and Quality of Life Improvement:

In addition to their direct anticancer effects, herbal medicines are often used to alleviate cancer-related symptoms and improve patients' overall quality of life. Herbal remedies such as ginger (*Zingiber officinale*) for chemotherapy-induced nausea and vomiting, St. John's wort (*Hypericum perforatum*) for depression and anxiety, and cannabis (*Cannabis sativa*) for pain management have been studied for their potential benefits in cancer supportive care. There is a growing interest in complementary and alternative medicine (CAM) in Eastern countries.^{20,21,22,23}

The use of herbal medicine has been high among Asian cancer patients.^{24,25,26} Similar reports are found in Malaysia in which biologically based therapies such as herbs and dietary supplements (87.9%) are the most frequent type of CAM used by cancer patients in South Peninsular Malaysia.²³ Traditional Chinese Medicine (TCM) is commonly used among the general and sick population for various reasons and purposes^{27,28,29} and up to 79% of cancer patients use TCM.^{29,30} Chinese Herbal Medicine (CHM), the major component of TCM, has been increasing in popularity among cancer patients.²⁰

Role of Artificial Intelligence in Cancer Care

Artificial intelligence, encompassing machine learning, deep learning, and natural language processing, has emerged as a powerful tool in cancer research and clinical practice. AI algorithms can analyse large datasets, including genomic, proteomic, and imaging data, to identify patterns and associations that may elude human cognition. In the context of cancer, AI-driven approaches hold promise for early detection, precision oncology, and treatment optimization. For instance, machine learning models can analyse medical imaging scans to detect tumors and predict treatment response, while natural language processing algorithms can extract valuable insights from unstructured clinical data, such as electronic health records and medical literature. The development of artificial intelligence technology such as deep learning and machine learning in anticancer drug research is reviewed by Guosheng Liang.³²

Integration of Herbal Medicine and AI in Cancer Therapy

The integration of herbal medicine and AI represents a novel paradigm in cancer care, leveraging the complementary strengths of both disciplines. AI algorithms can facilitate the systematic analysis of herbal compounds, elucidating their mechanisms of action, pharmacokinetics, and synergistic effects. Furthermore, machine learning models can predict the efficacy of herbal formulations based on patient-specific characteristics, such as genetic profiles and tumor biomarkers. Conversely, herbal medicine provides a vast repository of natural compounds that may serve as lead molecules for drug discovery and development. By combining the predictive power of AI with the therapeutic potential of herbal medicine, personalized and targeted cancer treatments can be tailored to individual patients, maximizing efficacy while minimizing adverse effects.

Challenges and Future Directions

Despite the promise of integrating herbal medicine and AI in cancer therapy, several challenges remain to be addressed. Regulatory hurdles, quality control issues, and standardization of herbal products pose significant barriers to their widespread adoption in clinical practice. Furthermore, the complex interplay between multiple bioactive compounds within herbal formulations presents challenges for data analysis and interpretation. Future research endeavours should focus on interdisciplinary collaborations between herbalists, oncologists, computational biologists, and regulatory agencies to validate the safety, efficacy, and reproducibility of herbal remedies. Moreover, advances in AI algorithms, including explainable AI and federated learning, hold potential for enhancing transparency, interpretability, and generalizability of predictive models in cancer care.

CONCLUSION

In conclusion, the integration of herbal medicine and artificial intelligence represents a promising approach to revolutionize cancer identification and treatment. By harnessing the synergistic potential of herbal compounds and AI algorithms, personalized and precision oncology can be realized, ushering in a new era of patient-centric cancer care. However, concerted efforts are needed to overcome existing challenges and translate scientific discoveries into clinically meaningful interventions. Through interdisciplinary collaboration and innovation, the quest for effective cancer therapies guided by nature and technology may ultimately transform the landscape of oncology.

Acknowledgement: The authors would like to acknowledge the contributions of colleagues and peers who provided valuable insights and suggestions during the preparation of this review.

Source of Funding: None.

Conflict of Interest: None.

Authors' Contribution: There is no contribution of other writers

REFERENCES

1. World Health Organization "Cancer". Retrieved 19 December 2018.
2. Croce CM. "Oncogenes and cancer". *N Engl J Med*. January 2008; 358: (5): 502–11.
3. Knudson AG. "Two genetic hits (more or less) to cancer". *Nat Rev Cancer*. November 2001; 1 (2): 157–62.
4. NHS Choices. Cancer – Signs and symptoms". Archived from the original on 8 June 2014. Retrieved 10 June 2014.
5. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al., Cancer statistic. *Cancer J. Clin.* 2005 Jan-Feb. 55(1): 10-30.
6. McCarthy J, Minsky ML, Rochester N, Shannon CE. A proposal for the Dartmouth summer research project on artificial intelligence, august 31, 1955. *AI Magazine*. 2006;27(4):12.
7. Yasser E-M, Honavar V, Hall A. Artificial Intelligence Research Laboratory. 2005
8. Lesperance ML, Olivotto IA, Forde N, Zhao Y, Speers C, Foster H, et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. *Breast Cancer Res Treat*. 2002; 76(2):137–143.
9. Saintot M, Mathieu-Daude H, Astre C, Grenier J, Simony-Lafontaine J, Gerber M. Oxidant-antioxidant status in relation to survival among breast cancer patients. *Int J Cancer*. 2002;97(5):574–579
10. Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. *Breast Cancer Res Treat*. 2006;95(3):199–209.
11. Willett WC, Stampfer MJ. What vitamins should I be taking, doctor? *N Engl J Med*. 2001;345(25):1819–1824.

12. Auyeung KK, Ko JK. Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. *Invest New Drugs*. 2010;28(1):1–13.
13. Au-Yeung KK, Liu PL, Chan C, Wu WY, Lee SS, Ko JK. Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPAR γ . *Cancer Invest*. 2008;26(7):708–717.
14. Baak JPAA, Gyllenhaal C, Liu L, Guo H, Block KI. Prognostic proof and possible therapeutic mechanisms of herbal medicine in patients with metastatic lung and colon cancer. *Integrative Cancer Therapies*. 2011;10(3):NP1–NP11.
15. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med*. 2001; 134(8):663–694.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials*. 1996; 17(1):1–12.
17. MacPherson H, White A, Cummings M, Jobst K, Rose K, Niemtow R. Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. *Complement Ther Med*. 2001;9(4):246–249.
18. Linde K, Jonas WB, Melchart D, Willich S. The methodological quality of randomized controlled trials of homeopathy herbal medicines and acupuncture. *Int J Epidemiol*. 2001;30(3):526–531.
19. Choi JY, Chang YJ, Hong YS. Complementary and alternative medicine use among cancer patients at the end of life: Korean national study. *Asian Pac J Cancer Prev*. 2012; 13:1419–24.
20. Jang A, Kang DH, Kim DU. Complementary and alternative medicine use and its association with emotional status and quality of life in patients with a solid tumor: A cross sectional study. *J Altern Complement Med*. 2017; 23:362–9.
21. Chun C, Lu HH, Chun CY, Hsin-Long L, Chang-Ju H, Chin-Chuan T et al. The prevalence, characteristics, and factors associated with purchasing Chinese herbal medicine among adults in Taiwan. *BMC Complement Altern Med*. 2017; 17:1–7.
22. Nurul Huda R, Aisyah A, Siew Hua G, Chun Sen L. Prevalence of traditional and complementary alternative medicine's use among cancer patients in South Peninsular Malaysia. *Asian Pac J Cancer Biol*. 2020; 5:19–26.
23. Yong C, Xiao-Ou S, Yutang G, Wanqing W, Zhi-Xian R, Fan J, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. *Breast Cancer Res Treat*. 2004; 85:263–70.
24. So Young K, Kyung Sook K, Jong Hyock P, Ji-Yeon S, Sung Kyeong K, Jae Hyun P, et al. Factors associated with discontinuation of complementary and alternative medicine among Korean cancer patients. *Asian Pac J Cancer Prev*. 2013; 14:225–30.
25. Mehmet Emin K, Hakan B, Ozan B, Ali S, Ahmet D, Alper S, et al. Depression, anxiety and quality of life through the use of complementary and alternative medicine among breast cancer patients in Turkey. *J Cancer Res Ther*. 2014; 10:962–6.
26. Farah N, Romy Abi F, Mohamad A, Yasmin A, Aya Z, Dania H. et al. Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: A cross-sectional study. *BMC Complement Altern Med*. 2015; 444:1–10
27. Barbara JS, Lindsey IB, Patricia MB, Tainya CC, Richard LN. Wellness-related use of common complementary health approaches among adults: United States. *Natl Health Stat Report*. 2015; 4:1–12.
28. Eunyoung K, Eun Joo Y, Sun-Mi K, Il Yong C, Sang Ah H, Do-Hoon K, et al. Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: A descriptive study. *Support Care Cancer*. 2012; 20:461–73.
29. Kang DH, McArdle T, Suh Y. Changes in complementary and alternative medicine use across cancer treatment and relationship to stress, mood, and quality of life. *J Altern Complement Med*. 2014; 20:853–9.
30. Gabriella MJ, Dawn LH, Laura F, Zaixing S, Wei-Yann T, Heather G. Complementary and alternative medicine use among US cancer survivors. *J Cancer Surviv*. 2016; 10:850–64.
31. Guosheng L, Wenguo F, Hui L, Xiao Z. The emerging roles of artificial intelligence in cancer drug development and precision therapy. *Biomed Pharmacother*. 2020;128:110255.